GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-09-22| Asia-Pacific

FDA Approves Samsung Bioepis and Biogen’s Lucentis Biosimilar

by Kathy Huang
Share To

On September 20th , Byooviz, a Lucentis biosimilar developed by Samsung Bioepis and Biogen, won FDA approval, making it the first ophthalmology biosimilar to be approved by the FDA. 

Byooviz (ranibizumab-nuna) references Roche’s blockbuster drug Lucentis. The alternative option to Lucentis is approved as treatment for three eye disorders: the “wet” form of neovascular age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV).

 

Roche’s Blockbuster Drug Lucentis

Lucentis is an antibody drug that blocks vascular endothelial growth factor (VEGF), a protein promoting abnormal growth of blood vessels in several eye diseases. By monthly injection, Lucentis blocks the abnormal pathway in the eyes, allowing them to function normally.

In 2020, Roche’s Lucentis generated more than $1.6 billion in sales, down from $1.8 billion in 2019. The decline will become more pronounced as rivals pop out from the biosimilars market.

 

Two Companies’ Ophthalmology Biosimilar Collaboration 

The FDA approval is based on a Phase 3 efficacy and safety study published this January, which enrolled 705 participants over 52 weeks. The results showed that Byooviz demonstrated equivalent safety and efficacy to Roche’s Lucentis, while the immunogenicity was also comparable. Byooviz may launch in the U.S. market starting from June 2022.

The collaboration between Samsung Bioepis and Biogen can be traced back to November 2019, when two companies partnered to develop two ophthalmology biosimilar candidates. Besides Byooviz, another biosimilar drug SB15 references Regeneron Pharmaceuticals’ Eylea. Samsung Bioepis launched a Phase 3 clinical trial for SB15 in late June.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Roche’s STI Test Clears FDA Potentially Becoming A Game-Changer for Fast, Accurate Diagnosis
2025-01-23
China’s Innovent Biologics Secures USD $1 Billion ADC Oncology Licensing Agreement with Roche
2025-01-06
LATEST
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top